Table of Contents
Two Italian ITP Studies 1. Borderline thrombocytopenia 2. Rituximab
Background
National Health and Nutrition Examination Survey III
PPT Slide
Objective of the study
Study design and setting
Patients
Methods
Age and sex distribution of 260 cases entering 6 mo observation
Platelet distribution of 260 cases entering 6 mo observation
Results: initial 6 months observation
PPT Slide
PPT Slide
Characteristics of 191 individuals with borderline thrombocytopenia who began follow-up
Prevalence of autoimmune markers in the cohort study and in controls
Outcome of individuals with borderline thrombo-cytopenia after the initial 6-mo observation period
PPT Slide
PPT Slide
PPT Slide
Summary of the results
Conclusions
PPT Slide
Pathophysiology: role of antibodies
Inhibition of antibody production
Rituximab Therapy for ITP
Phase I-II trials: Patients’ characteristics*
Phase I-II trials: Results
PPT Slide
Response Duration vs. Type of Response
Patient characteristics based on response to treatment
Duration of ITP and Response
Adverse events
Re-treatment in Relapsed CR/PR Patients
B-cell counts
B-cell Counts: CR vs PR
Median Anti-Platelet-Antibody Titers
CD20 MFI and Response to Rituximab
FCGR3A-158V/F Polymorphism and Response to Rituximab
Long Term Follow-Up of Patients with Immune Thrombocytopenic Purpura (ITP) Whose Initial Response to Rituximab Lasted a Minimum of 1 Year
Long Term Follow-Up of Patients with Immune Thrombocytopenic Purpura (ITP) Whose Initial Response to Rituximab Lasted a Minimum of 1 Year
Rituximab in ITP: not just a matter of B cells
Rituximab for adult ITP: Conclusions
|